Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 long-term safety and efficacy study of VX-659 triple combination in cystic fibrosis with F508del mutation
MOH_2018-05-31_002423Phase 3Not yet recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of bamocaftor, tezacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Planned start May 2018; status: not yet recruiting.
02
Drugs
bamocaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on MOH_2018-05-31_002423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-31_002423.